The Influence of Autologous Bone Marrow Stem Cell Transplantation on Matrix Metalloproteinases in Patients Treated for Acute ST-Elevation Myocardial Infarction

Abstract EN

Background.

Matrix metalloproteinase-9 (MMP-9), regulated by tissue inhibitor of metalloproteinase-9 (TIMP-1) and the extracellular matrix metalloproteinase inducer (EMMPRIN), contributes to plaque instability.

Autologous stem cells from bone marrow (mBMC) treatment are suggested to reduce myocardial damage; however, limited data exists on the influence of mBMC on MMPs.

Aim.

We investigated the influence of mBMC on circulating levels of MMP-9, TIMP-1, and EMMPRIN at different time points in patients included in the randomized Autologous Stem-Cell Transplantation in Acute Myocardial Infarction (ASTAMI) trial ( n = 100 ).

Gene expression analyses were additionally performed.

Results.

After 2-3 weeks we observed a more pronounced increase in MMP-9 levels in the mBMC group, compared to controls ( P = 0.030 ), whereas EMMPRIN levels were reduced from baseline to 2-3 weeks and 3 months in both groups ( P < 0.0001 ).

Gene expression of both MMP-9 and EMMPRIN was reduced from baseline to 3 months.

MMP-9 and EMMPRIN were significantly correlated to myocardial injury (CK: P = 0.005 and P < 0.001 , resp.) and infarct size (SPECT: P = 0.018 and P = 0.008 , resp.).

Conclusion.

The results indicate that the regulation of metalloproteinases is important during AMI, however, limited influenced by mBMC.